• Explore /
  • Poster
  • / <span>A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).</span.

A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

Abstract Poster

Authors

Kei Muro

Kei Muro

Aichi Cancer Center Hospital, Nagoya, Japan

Kei Muro , Tae Won Kim , Young Suk Park , Hiroyuki Uetake , Tomohiro Nishina , Hiroaki Nozawa , Hiroshi Matsumoto , Kentaro Yamazaki , Sae-Won Han , Keun-Wook Lee , Yanhong Deng , Marc E. Buyse , Taroh Satoh , Baek-Yeol Ryoo , Lin Shen , Satoru Iwasa , Satoshi Morita , Junichi Sakamoto , Rui-hua Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01996306

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr TPS780)

DOI

10.1200/jco.2016.34.4_suppl.tps780

Abstract #

TPS780

Poster Bd #

O11

Abstract Disclosures

Similar Posters

First Author: Masato Nakamura

First Author: T. Hansen

Poster

2014 Gastrointestinal Cancers Symposium

Cost differential among systemic therapies for colon cancer.

Cost differential among systemic therapies for colon cancer.

First Author: Hasan Nadeem

First Author: Sun Young Kim